Cardiopulmonary Disease Diagnostics and Treatment Market Set to Expand as AI-Enabled Diagnostics and Cardiac Care Advance
Market Estimation, Growth Drivers & Opportunities
The Cardiopulmonary Disease Diagnostics and Treatment Market is expanding as healthcare systems respond to the growing burden of cardiovascular and respiratory disorders. According to Maximize Market Research, the market was valued at USD 61.82 billion in 2025 and is projected to reach nearly USD 85.1 billion by 2032, registering a CAGR of 4.67% from 2026 to 2032. Cardiopulmonary diseases encompass disorders affecting both the heart and lungs, creating sustained demand for accurate diagnostics, monitoring technologies, and therapeutic solutions. An aging population, changing lifestyles, increasing awareness of cardiovascular conditions, and the growing need for early disease detection are key market drivers. The adoption of point-of-care testing and artificial intelligence in cardiovascular imaging is also creating new opportunities. AI can help clinicians analyze complex diagnostic information more efficiently, while connected monitoring devices can support earlier intervention. Opportunities are particularly strong in AI-assisted imaging, remote patient monitoring, wearable cardiopulmonary devices, advanced ECG systems, and minimally invasive treatment technologies.

* Download the Full Market Report: https://www.maximizemarketresearch.com/request-sample/67232/

U.S. Market Trends and Investment
The U.S. remains a major growth market as healthcare providers invest in advanced cardiovascular diagnostics, imaging, and AI-enabled clinical workflows. In March 2025, GE HealthCare launched the AltiX AI.i editions of Mac-Lab, CardioLab, and ComboLab to improve efficiency and interoperability in cardiac catheterization and electrophysiology procedures. GE HealthCare also launched Flyrcado, a PET myocardial perfusion imaging agent for detecting coronary artery disease, in select U.S. markets and highlighted new AI-powered cardiology innovations at ACC 2025. In April 2025, St. Luke's University Health Network announced an investment of more than $30 million in GE HealthCare MRI technology and services, supporting advanced imaging for cardiology and other specialties. Abbott also announced a new cardiovascular device manufacturing facility in Georgia, representing its second U.S. manufacturing investment in 2025 and reinforcing investment in domestic cardiovascular technology production. These developments demonstrate continued U.S. demand for advanced cardiopulmonary diagnostics and treatment technologies.

Market Segmentation: Largest Segment
Based on type, the Electrocardiogram (ECG) segment dominated the Cardiopulmonary Disease Diagnostics and Treatment Market. MMR attributes this leadership to the increasing adoption of point-of-care testing devices and the growing aging population. ECG remains a fundamental diagnostic technology for identifying and monitoring cardiac abnormalities, supporting its widespread use across healthcare settings. The broader diagnostic segment includes Holter monitoring, echocardiography, stress testing, cardiac catheterization, CT, MRI, SPECT, stress blood-pressure monitoring, and pulse oximetry, while treatment includes medication.

Key Players
Cardinal Health
Cosmed Medical
GE Healthcare
Halma plc
Hill-Rom Holdings, Inc.
Koninklijke Philips N.V. (Philips Healthcare)
MGC Diagnostics Corporation
NIHON KOHDEN CORPORATION
Schiller AG
Masimo Corporation
Vyaire Medical Inc.
Medtronic PLC
Boston Scientific Corporation
LivaNova PLC
Siemens Healthcare / Siemens Healthineers
St. Jude Medical, Inc.
Stryker Corporation
Baxter International Inc.
Abbott Laboratories
Becton Dickinson (BD)

Competitive Analysis
MMR identifies Cardinal Health, Cosmed Medical, GE Healthcare, Halma plc, Hill-Rom Holdings, Koninklijke Philips, MGC Diagnostics, Nihon Kohden, Schiller, Masimo, Vyaire Medical, Medtronic, Boston Scientific, LivaNova, Siemens Healthineers, St. Jude Medical, Stryker, Baxter International, Abbott Laboratories, and Becton Dickinson among the key companies covered in the market. The report does not disclose verified individual company market-share percentages; therefore, exact rankings by global share are not fabricated.

GE HealthCare is strengthening cardiopulmonary diagnostics through AI-enabled imaging and cardiology workflow technologies. In 2025, the company reported 100 FDA-authorized AI-enabled medical devices and increased R&D investment to integrate AI into medical devices across disease states.

Koninklijke Philips continued to advance AI-powered cardiac imaging in 2025. Its Transcend Plus cardiovascular ultrasound platform introduced FDA-cleared AI enhancements and 26 integrated cardiovascular ultrasound AI applications, designed to improve workflow and diagnostic confidence. Philips also introduced AI-enabled cardiac MR innovations aimed at faster imaging and improved diagnostic precision.

Siemens Healthineers continued developing AI-supported cardiovascular imaging. In 2025, its Syngo.CT Coronary Cockpit software introduced automated AI-driven plaque analysis and PCI planning for coronary CT imaging, supporting more efficient coronary artery disease management.

Medtronic continued investing in cardiac monitoring and AI-based cardiovascular care. In April 2025, the company announced a collaboration with Tempus to deploy artificial intelligence for identifying care gaps in heart valve disease. Its LINQ insertable cardiac monitors also demonstrated enhanced AFib detection capabilities in 2025.

Abbott Laboratories expanded cardiovascular technology investment in 2025, including plans for a new cardiovascular device manufacturing facility in Georgia. The company also introduced the TactiFlex Sensor Enabled ablation catheter, combining a flexible electrode tip with contact-force sensing to support atrial-fibrillation treatment.

Regional Analysis
USA: North America held the largest market share in 2022, according to MMR. The region's leadership is supported by changing lifestyles, growing awareness of heart disease, advanced healthcare infrastructure, and strong investment in diagnostic technologies.

UK: The UK benefits from established healthcare infrastructure and increasing adoption of advanced cardiovascular diagnostics, digital monitoring, and AI-supported clinical technologies.

Germany: Germany represents an important European market because of its advanced medical technology industry, aging population, and demand for sophisticated cardiovascular imaging and monitoring.

France: Cardiovascular diseases are a major health burden in France, creating continued demand for cardiopulmonary diagnosis and treatment. MMR specifically identifies cardiovascular disease prevalence as a factor supporting market growth in the country.

Japan: Japan's aging population and advanced healthcare infrastructure provide a strong foundation for ECG monitoring, cardiac imaging, respiratory diagnostics, and minimally invasive treatment technologies.

China: China's expanding healthcare infrastructure, aging population, rising awareness of cardiovascular conditions, and increasing adoption of advanced medical technologies create substantial long-term opportunities for cardiopulmonary diagnostics and treatment.

Related Reports:

Germany Healthcare Insurance Market https://www.maximizemarketresearch.com/market-report/germany-healthcare-insurance-market/226433/

Haemodialysis and Peritoneal Dialysis Market https://www.maximizemarketresearch.com/market-report/haemodialysis-and-peritoneal-dialysis-market/228429/

NLP in Healthcare and Life Sciences Market https://www.maximizemarketresearch.com/market-report/nlp-in-healthcare-and-life-sciences-market/228435/

Conclusion
The Cardiopulmonary Disease Diagnostics and Treatment Market is positioned for steady expansion as healthcare systems prioritize early diagnosis, continuous monitoring, and more precise treatment of heart and respiratory disorders. Growth from USD 61.82 billion in 2025 to nearly USD 85.1 billion by 2032 highlights the market's long-term potential. ECG remains the leading diagnostic technology, while AI-powered imaging, connected monitoring, point-of-care testing, advanced cardiac ultrasound, and automated clinical decision-support tools are creating new opportunities. In the coming years, the strongest growth is likely to come from technologies that combine diagnostic accuracy with faster workflows, remote monitoring, personalized care, and AI-enabled clinical insights.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
📞 +91 9607365656
📧 [email protected]